ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Sosei Heptares gets $26 million from Takeda for GPCR collaboration

by Ryan Cross
August 9, 2019 | APPEARED IN VOLUME 97, ISSUE 32

 

Sosei Heptares, a specialist in small-molecule drug discovery for G protein–coupled receptors (GPCRs), is collaborating with Takeda Pharmaceutical. Sosei will receive up to $26 million in near-term payments as it works on drug candidates against multiple GPCRs for gastrointestinal conditions. Sosei could earn more than $1.2 billion in future milestones. Sosei struck a similar deal with Genentech in July for a variety of diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment